from Lonza Group AG (isin : CH0013841017)
Lonza Group H1 2024 Performance Well On Track to Deliver Full-Year Outlook: Sales Up 1.8% CER and 29.2% CORE EBITDA Margin
Lonza Group AG / Key word(s): Half Year Results Ad hoc announcement pursuant to Art. 53 LR
Group Financial Summary
For more details on performance and financials, please refer to the Half-Year 2024 Presentation, Half-Year 2024 Report and Alternative Performance Measures (APM) 2024 Report.
1 Sales growth figures, expressed as a percentage (%), are at Constant Exchange Rate (CER) About Lonza Lonza is one of the world’s largest healthcare manufacturing organizations. Working across five continents, our global community of around 18,000 colleagues helps pharmaceutical, biotech and nutrition companies to bring their treatments to market. United by our vision to bring any therapy to life, we support our customers with a combination of technological insight, world-class manufacturing, scientific expertise, process excellence and innovation. Our work enables our customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit from life-saving and life-enhancing treatments. Our business is structured to meet our customers' complex needs across four divisions: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients. Our company generated sales of CHF 3.1 billion with a CORE EBITDA of CHF 893 million in Half-Year 2024. Find out more at www.lonza.com Lonza Contact Details Victoria Morgan Head of External Communications Daniel Buchta End of Inside Information |
| Language: | English |
| Company: | Lonza Group AG |
| Münchensteinerstrasse 38 | |
| 4052 Basel | |
| Switzerland | |
| Phone: | +4161 316 81 11 |
| Internet: | www.lonza.com |
| ISIN: | CH0013841017 |
| Valor: | 1384101 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1953479 |
| End of Announcement | EQS News Service |
1953479 25-Jul-2024 CET/CEST